Genome Editing in Human iPS Cells to Study and Cure Disease
Human iPS (induced pluripotent stem) cells have the potential to allow us to study diseases in virtually any type of human cell, and develop cell transplantation-based therapies. Our team is developing and improving genome editing technology in iPS cells. We are developing novel isogenic iPS cell-based disease models, and correcting mutations in iPS cells from patients, a critical step in transplantation-based therapies. Our current focus is on diseases affecting cardiomyocytes and hepatocytes. →More
2022. 1. 15. Comment on iPS cell therapy in Yomiuri Newspaper.
2021. 11. 18. Kanata Imamura and Yuga Yasuda join the lab as interns.
We revealed surprising smilarlities between cardiomyopathy and neurodgenerative diseases such as ALS (PDF).
2021. 10. 5. A review on CRISPR-Cas9 by Nakajima and Miyaoka is published in Clinical Immunology & Allergology (in Japanese)
2022. 5. 16. R&D Support Center Co.,Ltd. Seminar (Talk)
2022. 10. 5. Karasuyama Public Seminar "What is PCR?" (Seminar)